| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 95‐114 mm Hg after run‐in; 16‐week double‐blind treatment, forced‐titration of dose by 4 mg every 4 weeks to maximum 16 mg daily |
| Participants |
Perindopril 4‐16 mg once daily: n=117(65 males,52 females); mean age=55(10) years; baseline upright SBP=154(15) mm Hg, DBP=102(7) mm Hg; baseline supine SBP=157(16) mm Hg, DBP=100(5) mm Hg;
Perindopril 2‐8 mg twice daily: n=113(73 males,40 females); mean age=53(12) years; baseline upright SBP=150(15) mm Hg, DBP=101(6) mm Hg; baseline supine SBP=152(15) mm Hg, DBP=100(4) mm Hg;
Placebo: n=59(45 males,15 females); mean age=51(12) years; baseline upright SBP=161(14) mm Hg, DBP=103(8) mm Hg; baseline supine SBP=153(10) mm Hg, DBP=101(5) mm Hg |
| Interventions |
Perindopril 4 mg once daily (wk 0‐4), perindopril 8 mg once daily (wk 4‐8), Perindopril 12 mg once daily (wk 8‐12), perindopril 16 mg once daily (wk 12‐16);
Perindopril 2 mg twice daily (wk 0‐4), perindopril 4 mg twice daily (wk 4‐8), perindopril 6 mg twice daily (wk 8‐12), perindopril 8 mg twice daily (wk 12‐16);
Placebo |
| Outcomes |
Once daily dosing: upright and supine SBP/DBP 24 ± 2 h after last dose;
Twice daily dosing: upright and supine SBP/DBP 12 ± 2 h after last dose;
WDAE |
| Notes |
Used week 4 supine data only; BP change reported, SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Figure 1, p. 481; BP measurement device not reported; Jadad score=3; funding source= RW Johnson Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
